Exelixis (EXEL) Financials

Exelixis Inc (EXEL) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cancer. The company's financials provide insights into its performance and financial health. Let's dive into Exelixis Inc's income statement. The income statement reveals the company's revenues and expenses during a specific period. For Exelixis Inc, the total revenue for the latest reported period was $872.4 million. Moving on to the gross profit, it amounted to $687.8 million. This represents the revenue left after deducting the cost of goods sold. The company's operating expenses, including research and development, selling and marketing, and general administrative costs, totaled $295.6 million. Subtracting the operating expenses from the gross profit gives us the operating income or earnings before interest and taxes (EBIT), which stood at $392.2 million.

To get a more comprehensive view of the company's profitability, we can look at EBITDA, which is EBIT plus depreciation and amortization expenses. Exelixis Inc's EBITDA for the reporting period was $440.3 million. It demonstrates the company's earnings from core operations before accounting for non-cash expenses. Now, let's shift our focus to the company's net income attributable to stockholders. For Exelixis Inc, the net income from stockholders reached $341.8 million. This figure reflects the earnings remaining after deducting all expenses, including taxes and interest, and accounting for minority interests. As we move on to the balance sheet, we can examine the company's assets, liabilities, and shareholders' equity. Exelixis Inc reported total assets worth $3.3 billion. These assets consist of cash equivalents, investments, property, and other tangible and intangible assets. On the other hand, the company's total liabilities are recorded at $1.3 billion. These include short-term and long-term debt, accounts payable, and other obligations. The stockholders' equity, representing the portion of the company owned by shareholders, amounted to $1.98 billion. This indicates the net worth of the company after subtracting liabilities from assets. To understand Exelixis Inc's cash position, we can examine its cash flow statement. The cash flow statement outlines the movement of cash during the reported period. Exelixis Inc generated operating cash flow of $480.1 million, reflecting the cash generated from its core operations. The investing cash flow, which accounts for capital expenditures and acquisitions, was -$327.4 million. This indicates that the company invested more cash than it received from those activities. Finally, let's examine the financing cash flow, which includes activities such as debt repayments and equity issuances. For Exelixis Inc, the financing cash flow was -$137.8 million. This suggests that the company repaid more debt and bought back more stock than it received from financing activities. By analyzing these financials, investors can gain insights into Exelixis Inc's financial health and performance in the market.